EPO Market Stabilizes, But For How Long?
This article was originally published in RPM Report
Executive Summary
Amgen hoped it would be turning the page on the regulatory and reimbursement problems that dogged Aranesp and made 2007 a year to forget. But more negative data means another trip to an FDA advisory committee, and this time Wall Street is bracing for the worst.